Tang Capital Management Holds 5.7% Of Ardelyx After Its Drug Outlook Cuts
Kevin Tang reported shared authority over the same shares, while Ardelyx faces a lawsuit over its medicines' growth prospects.
Tang Capital Management reported a 5.7% stake in Ardelyx, a biopharmaceutical company selling prescription medicines for bowel and kidney conditions, in a passive ownership disclosure filed Tuesday. The position comes after Ardelyx reduced its commercial outlook in August and faces a securities lawsuit alleging it overstated its drugs' growth prospects.
Shared Authority Over 14.3 Million Shares
The position totaled 14,336,247 common shares as of November 9. Kevin Tang, Tang Capital Management's manager, reported the identical holding because he and the firm share voting and sale authority with related entities.
The holdings belong to Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III and Tang Capital Partners IV. Their respective positions were 2,663,183 shares, or 1.1%; 4,892,410 shares, or 1.9%; 3,350,677 shares, or 1.3%; and 3,429,977 shares, or 1.4%.
Tang Capital Management is general partner of the first two partnerships. Tang is chief executive of the latter two corporations, which Tang Capital Partners indirectly owns in full.
The reporting parties certified a passive purpose: they did not acquire or hold the shares to change or influence Ardelyx's control. The ownership percentages use 251,372,553 common shares outstanding as of October 27.
Insurance Restrictions Hit The Outlook
Ardelyx cut its full-year IBSRELA forecast in August and withdrew its long-term XPHOZAH revenue guidance. The company attributed slower IBSRELA patient starts to insurers restricting access and cited uncertainty over XPHOZAH's future growth.
Shares fell about 18% on August 7, from $4.87 to $4.00.
A securities lawsuit alleges Ardelyx and certain officers exaggerated the medicines' prospects while insurance approval requirements delayed patients starting treatment and prescriptions being filled. It seeks damages for alleged federal securities-law violations for investors who bought Ardelyx securities from January 13, 2025 through August 6, 2026.
Two Medicines, One Active Ingredient
Both medicines use tenapanor, which Ardelyx discovered and developed. IBSRELA is approved in the United States for adults with irritable bowel syndrome with constipation. XPHOZAH lowers blood phosphorus in adults with chronic kidney disease on dialysis who respond poorly to phosphate binders or cannot tolerate them.
Ardelyx uses its own specialty sales team and third-party contract manufacturers. It licenses tenapanor to partners in Canada, Japan and China, earning upfront payments, milestones and royalties, and charging to supply finished medicine or its drug substance.
The company is also conducting a late-stage tenapanor trial for chronic idiopathic constipation.
The deadline to seek appointment as lead plaintiff was Monday; investors need not serve in that role to participate in any recovery, according to the law firms' notice.
Sources
- SCHEDULE 13G — TANG CAPITAL MANAGEMENT, LLC re: Ardelyx, Inc. (ARDX) — SEC EDGAR
- Ardelyx Inc. (NASDAQ:ARDX) : Articles :: Law360 — law360.com
- ARDELYX (NASDAQ: ARDX) CLASS ACTION DEADLINE TODAY: Faruqi & Faruqi, LLP Reminds Investors of November 16, 2026 Lead Plaintiff Deadline — businesswire.com
- Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. — globenewswire.com
- ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law — prnewswire.com